Handling Competitive Conversations Without Disparaging the Competition
It happens in almost every detail. The HCP mentions a competitor product, asks a direct comparison question, or simply says, "I have been using X for years and it works fine." In that moment, the rep faces a choice. How they handle it determines whether they build credibility or erode it.
The instinct for many reps is to respond by highlighting the competitor's weaknesses. It feels logical. If the HCP understands why the competitor is inferior, surely they will switch. But in practice, disparaging the competition almost always backfires. It makes the rep look unprofessional, undermines trust, and can put the company in breach of industry codes.
According to Gartner's research, B2B buyers who receive helpful, relevant information during the sales process are 2.8 times more likely to experience a high degree of purchase ease. The emphasis is on helpful. Competitive conversations that are handled with professionalism and clinical evidence create purchase ease. Competitive conversations that devolve into product bashing do the opposite.
The good news is that handling competitive conversations well is a trainable skill. It requires preparation, a clear framework, and practice. Here is how to approach it.
The regulatory reality
Before discussing competitive strategy, it is worth being clear about the rules. In the UK, the ABPI Code of Practice prohibits companies from making disparaging references to competitor products. In the US, the PhRMA Code contains similar provisions. Across most regulated markets, comparative claims are restricted to those that can be supported by published, peer-reviewed evidence.
This means that reps cannot simply assert that their product is better. They can share approved data that demonstrates differentiation. They can discuss the clinical evidence that supports their product's profile. But making unsupported claims about a competitor, or implying that a competitor product is unsafe, is both unethical and potentially illegal.
These constraints are not limitations. They are guardrails that, when understood properly, actually help reps have better competitive conversations. When you cannot disparage, you must differentiate on evidence and value. That is a stronger position anyway.
Understanding the regulatory framework also protects the rep personally. An off-the-cuff comment about a competitor that crosses a compliance line can have serious consequences for the individual and the company. Training needs to make these boundaries clear and give reps the tools to work within them confidently.
The principles of effective competitive conversations
Before looking at specific scenarios, there are four principles that guide effective competitive conversations in life sciences.
The first is to acknowledge the competitor's strengths. This may feel counterintuitive, but it builds credibility immediately. An HCP who hears a rep say "X is a good product and I understand why many clinicians use it" is far more likely to listen to what comes next than one who hears "X has several problems."
The second is to differentiate on evidence. The competitive conversation should centre on what the data shows about your product, not what it allegedly shows about the competitor. Share your product's clinical evidence clearly and let the HCP draw their own conclusions about how it compares.
The third is to focus on patient outcomes. The question should never be "Why is our product better?" It should be "Which product best serves this patient population?" Framing the conversation around patient benefit elevates it from a sales pitch to a clinical discussion.
The fourth is to be comfortable with uncertainty. Sometimes the honest answer is "Our product is a good option for some patients, and the competitor product is a good option for others." This kind of honesty builds long-term credibility, even if it does not win the immediate conversation.
These principles sound simple, but applying them in the moment, when an HCP is asking a direct question and expecting a direct answer, requires preparation and practice. The instinct to compete aggressively is strong, and overcoming it requires a deliberate, trained alternative.
It also helps to remember that the HCP is not looking for a winner. They are looking for the best option for their patients. A rep who helps them think through that decision, rather than trying to win it, becomes a more trusted source of information over time.
Scenario one: the direct comparison request
An HCP looks up from their desk during a detail and says, "Tell me straight. Why should I use your product instead of X?"
The poor response. "Well, X actually has a number of limitations. Their dosing schedule is inconvenient, their side effect profile is worse, and their efficacy data is weaker." This response disparages the competitor, may include unsupported claims, and positions the rep as biased rather than informative.
The strong response. "That is a fair question. I cannot speak to X's clinical programme because that is not my data to present. What I can share is what our data shows. In our pivotal trial, we saw a statistically significant improvement in the primary endpoint, with a safety profile that our investigators described as manageable. I have the data here if you would like to look at it together."
Why it works. The rep acknowledges the question, sets a professional boundary, and immediately pivots to their own evidence. The HCP receives useful information without feeling that the rep is trying to manipulate their judgement.
Scenario two: the satisfied competitor user
An oncologist says, "I have been prescribing X for three years. My patients do well on it. I do not see a reason to change."
The poor response. "I think if you look at the latest data, you will see that X is not performing as well as people think. There are some real concerns about long-term outcomes." This implies the HCP has made poor decisions and casts doubt on the competitor without providing supporting evidence.
The strong response. "It is good to hear your patients are doing well. For many patients, X is a reasonable choice. Where we have seen particular interest from other oncologists is in the subset of patients who are intolerant to certain side effects or who have specific comorbidities. Our data in that population shows some promising results. Would it be useful for me to walk you through that subgroup analysis?"
Why it works. The rep validates the HCP's experience, avoids criticising their current choice, and introduces the product for a specific clinical niche rather than as a wholesale replacement. This is far less threatening and far more likely to open a productive conversation.
Scenario three: the formulary objection
A hospital pharmacist says, "Your product is not on our formulary. The committee reviewed it last year and chose X instead."
The poor response. "I think the committee may not have had the full picture. Our product is clearly superior when you look at the total cost of care." This undermines the committee's judgement and makes an unsubstantiated superiority claim.
The strong response. "I understand, and I respect the committee's process. Since that review, we have published additional data that I think the committee may find relevant, particularly around treatment persistence and real-world outcomes. Would it be possible for me to present this new evidence at the next formulary review? I am happy to work with whatever format the committee prefers."
Why it works. The rep respects the existing decision, introduces new evidence as the reason for reconsideration, and offers to work within the hospital's established process. This is collaborative rather than confrontational.
Scenario four: the KOL who advocates for a competitor
During a scientific exchange, a Key Opinion Leader says, "I was involved in the clinical programme for X. I think the evidence base is very strong."
The poor response. "With all due respect, I think there are some methodological concerns with those studies that are worth considering." Challenging a KOL's own research is almost never productive and can permanently damage the relationship.
The strong response. "That is a well-regarded programme, and I have read the data with interest. Our approach addresses the question from a slightly different angle. We focused on a patient population that is often underrepresented in clinical trials, and the outcomes were encouraging. I would value your perspective on how our data complements what you have already seen."
Why it works. The rep shows respect for the KOL's work, positions their own product as complementary rather than competitive, and invites the KOL's expert opinion. This opens a scientific dialogue rather than a competitive argument.
Training for these moments
Knowing these principles is one thing. Being able to apply them in real time, under pressure, with an HCP who is genuinely challenging, is another. Competitive conversations catch reps off guard precisely because they are unpredictable. The HCP may be neutral, curious, hostile, or testing the rep's knowledge.
This is where practice becomes essential. AI roleplay platforms like TrainBox allow reps to rehearse competitive scenarios repeatedly, facing different HCP personas with different attitudes and objections. The practice builds the pattern recognition and composure that allow reps to handle competitive questions smoothly in the field.
The reps who handle competitive conversations best are not the ones with the sharpest put-downs or the most aggressive positioning. They are the ones who have practised enough that professionalism, evidence-based differentiation, and patient-focused framing feel natural. That kind of composure is not innate. It is the product of deliberate preparation and repeated rehearsal.
Preparation also means staying current. Competitive landscapes shift as new data is published, new indications are approved, and new products enter the market. Reps need regular updates on the competitive environment and opportunities to practise how they will address new competitive scenarios as they emerge.
The best sales teams build competitive conversation practice into their regular training rhythm rather than treating it as a one-off workshop. Monthly or quarterly sessions that focus on new competitive developments keep reps sharp and confident.
The credibility equation
Every competitive conversation is a test of credibility. The HCP is evaluating not just the clinical evidence, but the rep's integrity and professionalism. A rep who disparages a competitor loses credibility. A rep who acknowledges complexity and presents evidence fairly gains it.
Over time, these interactions compound. The rep who consistently handles competitive questions with professionalism becomes the rep that HCPs trust, the one they are willing to make time for, the one whose clinical evidence they take seriously.
Conversely, a single poorly handled competitive conversation can undo months of relationship building. An HCP who hears a rep disparage a product they have been prescribing successfully will question not just that statement, but everything else the rep has told them. The stakes of these moments are higher than most reps realise.
That trust is worth far more than winning any single competitive argument. And the way to earn it is not through cleverness or aggression, but through the consistent, professional, evidence-based approach that comes from thorough preparation and regular practice.
TrainBox helps life science teams practise real conversations so they're ready when it matters.